Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy

Last updated: March 7, 2025
Sponsor: Sidrah Lodhi
Overall Status: Completed

Phase

4

Condition

Diabetes Mellitus Types I And Ii

Diabetes Mellitus, Type 2

Diabetes And Hypertension

Treatment

Placebo

Pirfenidone

Clinical Study ID

NCT06224790
483/RC/KEMU/2022
  • Ages 30-65
  • All Genders

Study Summary

The purpose of this study is to determine the effectiveness & safety of pirfenidone in type 2 diabetic patients with diabetic nephropathy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diabetic Nephropathy Stage 3 (eGFR 30-59 mL/min/1.73m2) Type 2 Diabetes HbA1c <7.5%Patient taking ACEi/ARB for at least 3 months BP <140/90

Exclusion

Exclusion Criteria:

  • History of photosensitivity rash History of decompensated liver or cardiac diseaseHistory of urinary tract infection Pregnancy or lactation History of nephrotoxicdrugs or hakeem medication Polycystic kidney disease History of autoimmune diseaseHistory of hypersensitivity to study drugs

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 4
Study Start date:
March 10, 2024
Estimated Completion Date:
March 07, 2025

Connect with a study center

  • King Edward Medical University

    Lahore, Punjab 54000
    Pakistan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.